Verificando…
Traduzido automaticamente. Doses e advertências: confira o original em inglês. Ler em inglês
Início / Registado na Nigéria / Valsartan 80 mg Tablets_

Valsartan 80 mg Tablets_

NAFDAC Reg. No. A4-100919 · Drug

Registered with NAFDAC. Registration activeAs of 29 October 2026 · synced automatically from official sources.
Product
Valsartan 80 mg Tablets_
Número NAFDAC
A4-100919
Princípio ativo
Valsartan
Dosagem
80 mg
Forma
Tablet
Tamanho da embalagem
3 x 10's (in Alu Alu blisters)
Manufacturer
Not listed
Applicant (holder)
Society for Family Health
Approved
27 Jun 2024
Situação
Active View on NAFDAC ↗
Registro válido até
26 Jun 2029
Alertas da OMS
None found
Community reports
None
Times checked
0

About the medicine: Valsartan: uses, dosage and brands worldwide

What we found

  • Valsartan 80 mg Tablets_ is on the NAFDAC register with an active registration (A4-100919). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Valsartan 80 mg Tablets_

O que diz a bula oficial. Se um médico receitou, siga a receita. Se a bula da sua caixa for diferente, vale a da sua caixa.

Advertência grave: FETAL TOXICITY When pregnancy is detected, discontinue valsartan as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 ) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue valsartan as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
Para quem é

Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lowe …

Como tomar e com que frequência
  • Indication Starting Dose Dose Range * Hypertension Adult 80-160 mg once daily 80-320 mg once daily 1-16 years 1 mg/kg once daily Up to 40 mg daily 1-4 mg/kg once daily Up to 160 mg daily Heart Failure 40 mg twice daily 40-160 mg twice daily Post-Myocardial Infarction 20 mg twice daily 20-160 mg twice daily * As tolerated by patient Important Dosage and Preparation Information Valsartan tablets and oral suspension are not substitutable on a milligram-per-milligram basis
  • Do not combine two dosage forms to achieve the total dose
  • The systemic exposure to valsartan (AUC) is 60% higher with the suspension compared to tablets [see Clinical Pharmacology ]
  • Use of the oral suspension is recommended: in pediatric patients aged 1 to 5 years in patients >5 years of age who cannot
  • Swallow tablets and in pediatric patients for whom the calculated dose (mg/kg) does not correspond to the available tablet strengths of valsartan
  • When switching between suspension and tablets, the dose of valsartan may need to be adjusted
  • Preparation of Suspension (for 160 mL of a 4 mg/mL suspension) • Add 80 mL of Ora-Plus ® * oral suspending vehicle to an amber glass bottle containing 8 valsartan 80 mg tablets and shake for a minimum of 2 minutes. • Allow the suspension to stand for a minimum of 1 hour. • After the standing time, shake the suspension for a minimum of 1 additional minute. • Add 80 mL of Ora-Sweet SF ® * oral sweetening vehicle to the bottle and shake the suspension for at least 10 seconds to disperse the ingredients. …
Strengths it comes in

40 mg are scored yellow, capsule-shaped, biconvex, film-coated tablets debossed with “341” and bisect between 3 and 41 on one side, and “HH” on the other side. 80 mg are brown, capsule-shaped, biconvex, film-coated tablets debossed with “342” on one side and “HH” on the other side. …

While you are taking it
  • Advise the patient to read the FDA-approved patient labeling (Patient Information)
  • Pregnancy : Advise female patients of childbearing age about the consequences of exposure to valsartan during pregnancy
  • Discuss treatment options with women planning to become pregnant
  • Ask patients to report pregnancies to their healthcare provider as soon as possible [see Warnings and Precautions , Use in Specific Populations ]
  • Lactation: Advise women not to breastfeed during treatment with valsartan [see Use in Specific Populations ]. …
Talk to a doctor first if
  • Do not use in patients with known hypersensitivity to any component
  • Do not coadminister aliskiren with valsartan in patients with diabetes [ see Drug Interactions ]
  • Known hypersensitivity to any component
  • Do not coadminister aliskiren with valsartan in patients with diabetes
Medicines it may not mix with

Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7.1 ) Non-Steroidal Anti-Inflammatory Drug (NSAID) use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7.2) Dual inhibition of the Renin-Angiotensin System (RAS): Increased risk of renal impairment, hypotension, and hyperkalemia ( 7.3 ) Lithium: Increases in serum lithium level and lithium toxicity ( 7.4 ) 7.1 Agents Increasing Serum Potassium Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, tr …

Warnings

Observe for signs and symptoms of hypotension ( 5.2 ) Monitor renal function and potassium in susceptible patients ( 5.3 , 5.4 ) 5.1 Fetal Toxicity Valsartan can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. …

Possíveis efeitos colaterais

Hypertension: Most common adverse reactions are headache, dizziness, viral infection, fatigue and abdominal pain ( 6.1 ) Heart Failure: Most common adverse reactions are dizziness, hypotension, diarrhea, arthralgia, back pain, fatigue and hyperkalemia ( 6.1 ) Post-Myocardial Infarction: Most common adverse reactions which caused patients to discontinue therapy are hypotension, cough and increased blood creatinine ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Solco Healthcare US, LLC at 1-866-257-2597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. …

Pregnancy and breastfeeding

IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended ( 8. 2) Pediatrics : Use of valsartan tablets is not recommended in children less than 1 year of age ( 6.1 , 8.4 , 13.2 ) 8.1 Pregnancy Risk Summary Valsartan can cause fetal harm when administered to a pregnant woman. …

If you take too much

Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. Depressed level of consciousness, circulatory collapse and shock have been reported. If symptomatic hypotension should occur, institute supportive treatment. Valsartan is not removed from the plasma by hemodialysis. …

Se esquecer uma dose

Tome assim que lembrar, a menos que esteja quase na hora da próxima dose. Nesse caso, pule a dose esquecida. Nunca tome duas doses de uma vez para compensar. Confira a bula, pois alguns medicamentos são diferentes.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-01-01.

Label for valsartan, the active ingredient registered with NAFDAC.

Check your pack of Valsartan 80 mg Tablets_

Add the expiry date on your pack for a full Trust Score.

Ou tire fotos da caixa
Restam 3 verificações grátis hoje Fontes oficiais: FDA dos EUA · EMA (UE) · NAFDAC · alertas da OMS

About Valsartan 80 mg Tablets_

What is in Valsartan 80 mg Tablets_?

Valsartan 80 mg Tablets_ contains Valsartan (80 mg), as tablet, according to its NAFDAC registration record.

Is Valsartan 80 mg Tablets_ registered with NAFDAC?

Yes. Valsartan 80 mg Tablets_ is listed on the NAFDAC register under registration number A4-100919, and its registration is active as of 29 October 2026.

Has Valsartan 80 mg Tablets_ been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Valsartan 80 mg Tablets_ in our automatically synced alert list.

How can I check that my pack of Valsartan 80 mg Tablets_ is genuine?

Run a free authenticity scan with the NAFDAC number A4-100919, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Valsartan 80 mg Tablets_?

Follow your prescription or the leaflet in your pack. The official label says: Indication Starting Dose Dose Range * Hypertension Adult ( 2.2 ) 80-160 mg once daily 80-320 mg once daily 1-16 years ( 2.3 ) 1 mg/kg once daily Up to 40 mg daily 1-4 mg/kg once daily Up to 160 mg daily Heart Failure ( 2.4 ) 40 mg twice daily 40-160 mg twice daily Post-Myocardial Infarction ( 2.5 ) 20 mg twice daily 20-160 mg twice daily * As tolerated by patient 2.1 Important …

What is Valsartan 80 mg Tablets_ used for?

Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myo (Summarised from the official U.S. FDA label for valsartan. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Valsartan 80 mg Tablets_? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.